Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Jan 25, 2019
Finance
Kurma’s Munich move
...Kurma’s Munich office, told BioCentury that Germany’s first generation of VCs poured money into the then-
nascent biotech
...
Read More
BioCentury
|
Apr 21, 2017
Product R&D
Making marks at AACR
...cancer, no gene expression signatures were predictive of antitumor activity by Stivarga. 5036 / 11
Nascent Biotech Inc.
...
Read More
BioCentury
|
Apr 14, 2014
Finance
Guest Commentary: Reducing the burden of disclosure
...about a company. That may not always be true, particularly for smaller biotechs. For a
nascent biotech
...
Read More
Items per page:
10
1 - 3 of 3
BioCentury
|
Jan 25, 2019
Finance
Kurma’s Munich move
...Kurma’s Munich office, told BioCentury that Germany’s first generation of VCs poured money into the then-
nascent biotech
...
Read More
BioCentury
|
Apr 21, 2017
Product R&D
Making marks at AACR
...cancer, no gene expression signatures were predictive of antitumor activity by Stivarga. 5036 / 11
Nascent Biotech Inc.
...
Read More
BioCentury
|
Apr 14, 2014
Finance
Guest Commentary: Reducing the burden of disclosure
...about a company. That may not always be true, particularly for smaller biotechs. For a
nascent biotech
...
Read More
Items per page:
10
1 - 3 of 3
Previous page
Next page